Patents Assigned to The Trustees of the University of Pennsylvania
  • Publication number: 20240384298
    Abstract: Provided herein are novel AAV capsids and recombinant AAV vectors comprising the same. In one embodiment, vectors employing a novel AAV capsid show increased transduction of a selected target tissue as compared to a prior art AAV.
    Type: Application
    Filed: September 30, 2022
    Publication date: November 21, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Qiang Wang, Jenny Agnes Sidrane, James M. Wilson
  • Patent number: 12145216
    Abstract: A laser is used to controllably generate and propagate cleaves to produce a cleaved surface along the {111} crystallographic plane in diamonds.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 19, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Lee Bassett, Samuel Parks, Richard Grote, David Hopper
  • Patent number: 12145816
    Abstract: Provided are systems and methods for inducing strain fields to give rise to controllable wrinkle patterns in a variety of substrates. Also provided are articles having persistent wrinkling patterns thereon.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 19, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daeyeon Lee, Kathleen Stebe, Shu Yang, Xu Zhang
  • Patent number: 12139550
    Abstract: The present invention relates to antibodies, binding polypeptides, and scFvs specific for fibroblast activation protein (FAP) capable of cross reacting with canine, mouse, and human FAP.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: November 12, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ellen Puré, Leslie Todd
  • Patent number: 12138305
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: November 12, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Drew Weissman, Norbert Pardi
  • Patent number: 12138366
    Abstract: The present disclosure is concerned with magneto-patterned cell-laden hydrogel materials and methods of making and using those materials. The disclosed materials are useful for, among other things, repair of tissue defects, e.g., tissue at a tissue interface such as a bone-cartilage interface.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: November 12, 2024
    Assignees: The United States Government as Represented by the Department of Veterans Affairs, The Trustees of the University of Pennsylvania
    Inventors: Hannah M. Zlotnick, Andrew Todd Clark, Robert L. Mauck, Xuemei Cheng
  • Patent number: 12134757
    Abstract: Described herein is a beads-free bioprocessor as an automated and cost-effective T cell processing and manufacturing platform. T cells are a core component in CAR T cell therapies for cancer treatment, but are difficult to manufacture to scale in clinically relevant quantities. The 3D bioprocessor provides an alternative device that is scalable, beads-free, easy-to-use, and cost-effective for using CAR T cell therapy in cancer immunotherapy. Besides CAR T cell application, this platform technology has potential for many other applications such as cancer cell isolation.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: November 5, 2024
    Assignees: Southwest Research Institute, The Trustees Of The University Of Pennsylvania
    Inventors: Jian Ling, Kreg A. Zimmern, Michael C. Milone
  • Publication number: 20240358865
    Abstract: The present disclosure is generally directed to quinolinyl and pyridinyl containing compounds targeting on alpha-synuclein for neurological diseases. These compounds, particularly radiolabeled versions of these compounds, can be particularly useful in PET scans targeting diseases such as Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA).
    Type: Application
    Filed: April 25, 2024
    Publication date: October 31, 2024
    Applicants: Washington University, The Trustees of the University of Pennsylvania, University of Pittsburgh – Of the Commonwealth System of Higher Education
    Inventors: Zhude Tu, Yanbo Yu, Lin Qiu, Paul Kotzbauer, Robert Mach, Chester Mathis
  • Patent number: 12128069
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 29, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventor: Steven M. Albelda
  • Patent number: 12128136
    Abstract: The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: October 29, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Edward E. Morrisey, Jason A. Burdick, Leo Wang
  • Publication number: 20240350595
    Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.
    Type: Application
    Filed: December 21, 2023
    Publication date: October 24, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Daniel Rader, Devin Christopher, Anna P. Tretiakova
  • Patent number: 12122829
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: October 22, 2024
    Assignees: The Trustees of the University of Pennsylvania, Fondazione IRCCS Istituto Nazionale Dei Tumori
    Inventors: Daniel J. Powell, Jr., Mariangela Figini, Silvana Canevari
  • Patent number: 12122820
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 22, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Publication number: 20240344196
    Abstract: A nanoscale plate structure includes base plates and rib plates with nanoscale thickness and macroscopic lateral dimensions. The base plate resides in the first plane, the ribs can reside out-of-plane and form at least one strengthening rib, and additional base plates can reside in planes parallel to the first plane. The strengthening rib can be patterned such that there is no straight line path extending through a lateral dimension of the plate structure that does not intersect the at least one base plate and the at least one strengthening rib. The plates and ribs used in the structure have a thickness between about 1 nm and about 100 nm. The plate structures can be fabricated using a conformal deposition method including atomic layer deposition.
    Type: Application
    Filed: March 22, 2024
    Publication date: October 17, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Igor Bargatin, Keivan Davami
  • Patent number: 12116387
    Abstract: Provided herein are synthetic peptides with enhanced antimicrobial and antibiofilm characteristics, and are biocompatible with mammalian cellular systems. The disclosed synthetic antimicrobial moieties include a mastoparan peptide having SEQ ID NO:1 and a pentapeptide motif formed from phenylalanine, leucine, proline, and two isoleucine residues, wherein the pentapeptide motif is conjugated the N-terminus of the mastoparan peptide. Also provided are compositions comprising the synthetic peptides, as well as methods of treating a microbial infection or removing a biofilm using the peptides.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: October 15, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Marcelo Der Torossian Torres, Cesar de la Fuente-Nunez, Gislaine G. O. Silva, Octavio L Franco
  • Patent number: 12116418
    Abstract: The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (FAP) for use in treating diseases, disorders or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 15, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Steven A. Albelda, Ellen Puré, Leslie Todd
  • Patent number: 12117713
    Abstract: Nonlinear on-chip optical devices using AlScN are described herein. In one aspect, an optical component having nonlinear characteristics can include a first substrate defining a refractive index; and a nonlinear layer, the nonlinear layer disposed on the first substrate, the nonlinear layer comprising an amount of scandium (Sc), and the nonlinear layer defining a refractive index that is higher than the refractive index of the first substrate.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: October 15, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Valerie J. Yoshioka, Jian Lu, Zichen Tang, Jicheng Jin, Roy H. Olsson, III, Bo Zhen
  • Patent number: 12110331
    Abstract: The present invention relates to canine antibodies, binding polypeptides, and scFvs specific for canine cytotoxic T lymphocyte associated protein 4 (CTLA-4).
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: October 8, 2024
    Assignees: The Trustees of the University of Pennsylvania, Vetigenics, Inc.
    Inventors: Nicola J. Mason, Donald L. Siegel, Nicholas Chester
  • Patent number: 12111317
    Abstract: The present invention provides compositions and methods for detecting and isolating disseminated tumor cells (DTCs) from breast cancer in a bone marrow aspirate of a subject. The invention further provides methods of treating breast cancer in the subject.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: October 8, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lewis Chodosh, Elizabeth Chislock
  • Patent number: 12109258
    Abstract: Provided herein are sequences of Plasmodium spp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 8, 2024
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Emma Reuschel, Bernadette Ferraro, Ahmed S. I. Aly